Bluebird Bio ' s " Impressive " Killer T-Cells Battle Myeloma, But Are Not A Cure Yet

New data show that at a high dose, the CAR-T therapy developed by Bluebird and Celgene shrank tumor in 95 percent of patients and made cancer undetectable in 50 percent. The cancer still returned for most patients.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: NASDAQ:CELG NASDAQ:BLUE Source Type: news